Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity (2022 - 2026)

Sagimet Biosciences' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $107.8 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 26.28% year-over-year to $107.8 million in Q1 2026; TTM through Mar 2026 was $490.0 million, a 26.88% decrease from a year earlier, with the FY2025 full-year figure at $116.5 million, down 27.32% from the prior year.
• Liabilities and Shareholders Equity slipped to $107.8 million in Q1 2026 per SGMT's latest filing, from $116.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $194.5 million in Q1 2024 and bottomed at $21.5 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $128.4 million (2025), against an average of $123.8 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 779.24% in 2024 and slipped 27.32% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $33.0 million in 2022, then jumped by 192.81% to $96.7 million in 2023, then soared by 65.7% to $160.3 million in 2024, then declined by 27.32% to $116.5 million in 2025, then retreated by 7.49% to $107.8 million in 2026.
• Per Business Quant, the three latest SGMT Liabilities and Shareholders Equity figures stand at $107.8 million (Q1 2026), $116.5 million (Q4 2025), and $128.4 million (Q3 2025).